GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeImmune Inc (OTCPK:GBIM) » Definitions » 5-Year Yield-on-Cost %

GlobeImmune (GlobeImmune) 5-Year Yield-on-Cost % : 0.00 (As of May. 21, 2024)


View and export this data going back to 2014. Start your Free Trial

What is GlobeImmune 5-Year Yield-on-Cost %?

GlobeImmune's yield on cost for the quarter that ended in Mar. 2016 was 0.00.


The historical rank and industry rank for GlobeImmune's 5-Year Yield-on-Cost % or its related term are showing as below:



GBIM's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.615
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of GlobeImmune's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, GlobeImmune's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlobeImmune's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeImmune's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where GlobeImmune's 5-Year Yield-on-Cost % falls into.



GlobeImmune 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of GlobeImmune is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

GlobeImmune  (OTCPK:GBIM) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


GlobeImmune 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of GlobeImmune's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


GlobeImmune (GlobeImmune) Business Description

Traded in Other Exchanges
N/A
Address
1450 Infinite Drive, Louisville, CO, USA, 80027
GlobeImmune Inc is a US-based biopharmaceutical company which focuses on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen platform. It develops few Tarmogen product candidates for infectious disease and multiple cancer indications. The pipeline products of the company are GS-4774, GI-19000, GI-2010, GI-18000 which targets HBV and HIV antigens, TB antigens and Delta virus antigens and Oncology product candidates such as GI-6207, GI-6301, GI4000 which targets Carcinoembryonic antigen, Brachyury, and Mutated Ras.
Executives
Augustine Lawlor director 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Daniel J Mitchell director
S. Edward Torres director C/O LILLY VENTURES FUND I LLC, 115 W. WASHINGTON ST, STE 1680 SOUTH, INDIANAPOLIS IN 46204
Healthcare Ventures Vii Lp other: Former 10% Owner 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
John W Littlechild other: Former 10% Owner 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
James H Cavanaugh other: Former 10% Owner 265 HOTHORPE LANE, VILLANOVA PA 19085
Harold R Werner other: Former 10% Owner C/O HEALTHCARE VENTURES LLC, 44 NASSAU STREET, PRINCETON NJ 08542
Christopher Mirabelli other: Former 10% Owner 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Healthcare Partners Vii, L.p. other: Former 10% Owner 44 NASSAU STREET, PRINCETON NJ 08542
J William Freytag director
Rodell Timothy C Jr director, officer: CEO & Pres 201 MIDLAND AVE, ASPEN CO 81611
Celgene Corp /de/ 10 percent owner 86 MORRIS AVENUE, SUMMIT NJ 07901
Morgenthaler Partners Vii Lp 10 percent owner 50 PUBLIC SQUARE, SUITE 2700, CLEVELAND OH 44113

GlobeImmune (GlobeImmune) Headlines

No Headlines